Document is current
Any future updates will be listed below
-
Authors
Ahuja, Rahul
Vishwakarma, Preeti
Kumar, Varun
Khatri, Ritika
Chatterjee, Ananya
Mishra, Surbhi
Rizvi, Zaigham Abbas
Singh, Anup
Kaur, Gurleen
Maithil, Vikas
Tarane, Kunal
Chauhan, Akanksha
Singh, Sarjeet
Yadav, Pooja
Yadav, Devendra
Sinha, Sangita Kumari
Ali, Syed Khalid
Chatterjee, Abhisek
Priyadarsiny, Priyanka
Awasthi, Amit
Prasad, Vidya Mangala
Ahmed, Shubbir
Samal, Sweety
-
Funding
Funding for this research was provided by:
Department of Biotechnology, Ministry of Science and Technology, India
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 25 May 2025
First Online: 6 June 2025
Competing interests
: The Translational Health Science and Technology Institute (THSTI) has filed patent PCT International Application No. PCT/IB2022/059713||202111046243|| Multiepitope Self-Assembled Nanoparticle vaccine platform (msn-vaccine platform) and uses thereof, and listed S.S., S.A., R.K., and A.A., and technology has been transferred to Panacea Biotec Ltd, India for development of DP and DS. Indian Patent Provisional Application No.: 202411072889 filed on September 26, 2024, Title: an engineered polypeptide complex for generating protective immune responses against monkeypox (MPXV). All other authors declare no competing interests.
